A comprehensive meta-analysis of 59 randomized trials involving 29,692 heart failure patients found SGLT2 inhibitors reduced all-cause mortality by 10% and heart failure hospitalizations by 26%. The diabetes drugs, including empagliflozin and dapagliflozin, showed consistent benefits across the full spectrum of heart failure patients, with zero statistical heterogeneity between studies suggesting remarkably consistent effects. This represents one of the largest systematic reviews of SGLT2 inhibitors in heart failure to date. The cardiovascular benefits of these sodium-glucose transporters extend far beyond their original diabetes indication, positioning them as foundational heart failure therapy alongside ACE inhibitors and beta-blockers. The mechanism likely involves improved cardiac metabolism and reduced cardiac workload rather than glucose control alone. While genital infections increased nearly four-fold, serious adverse events actually decreased, suggesting a favorable risk-benefit profile. However, this preprint awaits peer review, and results could change during editorial scrutiny. The findings are largely confirmatory rather than paradigm-shifting, reinforcing existing clinical guidelines that already recommend SGLT2 inhibitors for heart failure patients regardless of diabetes status.